JOP20230173A1 - أشطر إطالة العمر-النصفي وطرق استخدامها - Google Patents
أشطر إطالة العمر-النصفي وطرق استخدامهاInfo
- Publication number
- JOP20230173A1 JOP20230173A1 JOJO/P/2023/0173A JOP20230173A JOP20230173A1 JO P20230173 A1 JOP20230173 A1 JO P20230173A1 JO P20230173 A JOP20230173 A JO P20230173A JO P20230173 A1 JOP20230173 A1 JO P20230173A1
- Authority
- JO
- Jordan
- Prior art keywords
- extending
- effective methods
- molecules
- extending lifespan
- investigation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144696P | 2021-02-02 | 2021-02-02 | |
| PCT/US2022/014728 WO2022169757A1 (en) | 2021-02-02 | 2022-02-01 | Half-life extending moieties and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230173A1 true JOP20230173A1 (ar) | 2023-07-30 |
Family
ID=80735776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0173A JOP20230173A1 (ar) | 2021-02-02 | 2023-07-30 | أشطر إطالة العمر-النصفي وطرق استخدامها |
Country Status (18)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260109751A1 (en) * | 2022-12-30 | 2026-04-23 | Eli Lilly And Company | Methods of dulaglutide purification using hydrophobic interaction chromatography |
| EP4731669A2 (en) * | 2023-06-21 | 2026-04-29 | Eli Lilly and Company | Compounds for the delivery of granulin across the blood brain barrier |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259802A1 (en) * | 2008-03-31 | 2010-12-15 | Glaxo Group Limited | Drug fusions and conjugates |
| AU2012280474A1 (en) * | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2015231170B2 (en) * | 2014-03-20 | 2019-10-03 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
| WO2018104444A1 (en) * | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3807311A4 (en) * | 2018-04-24 | 2022-01-26 | National Research Council of Canada | SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
-
2022
- 2022-02-01 JP JP2023546450A patent/JP2024506145A/ja active Pending
- 2022-02-01 CA CA3204225A patent/CA3204225A1/en active Pending
- 2022-02-01 KR KR1020237025927A patent/KR20230137342A/ko active Pending
- 2022-02-01 EP EP22709849.8A patent/EP4288452A1/en active Pending
- 2022-02-01 US US18/259,500 patent/US20240316154A1/en active Pending
- 2022-02-01 MX MX2023009006A patent/MX2023009006A/es unknown
- 2022-02-01 WO PCT/US2022/014728 patent/WO2022169757A1/en not_active Ceased
- 2022-02-01 AU AU2022217754A patent/AU2022217754A1/en active Pending
- 2022-02-01 CN CN202280012629.0A patent/CN116802209A/zh active Pending
- 2022-02-01 CR CR20230366A patent/CR20230366A/es unknown
- 2022-02-01 PE PE2023002220A patent/PE20240233A1/es unknown
-
2023
- 2023-06-30 ZA ZA2023/06754A patent/ZA202306754B/en unknown
- 2023-07-03 IL IL304219A patent/IL304219A/en unknown
- 2023-07-27 DO DO2023000149A patent/DOP2023000149A/es unknown
- 2023-07-27 CO CONC2023/0010002A patent/CO2023010002A2/es unknown
- 2023-07-30 JO JOJO/P/2023/0173A patent/JOP20230173A1/ar unknown
- 2023-08-01 EC ECSENADI202358246A patent/ECSP23058246A/es unknown
- 2023-08-02 CL CL2023002285A patent/CL2023002285A1/es unknown
-
2025
- 2025-10-02 CL CL2025003008A patent/CL2025003008A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240233A1 (es) | 2024-02-16 |
| ECSP23058246A (es) | 2023-09-29 |
| CO2023010002A2 (es) | 2023-09-08 |
| JP2024506145A (ja) | 2024-02-09 |
| KR20230137342A (ko) | 2023-10-04 |
| CR20230366A (es) | 2023-10-03 |
| CN116802209A (zh) | 2023-09-22 |
| ZA202306754B (en) | 2025-02-26 |
| CL2023002285A1 (es) | 2024-02-23 |
| AU2022217754A1 (en) | 2023-07-27 |
| DOP2023000149A (es) | 2023-09-15 |
| CA3204225A1 (en) | 2022-08-11 |
| EP4288452A1 (en) | 2023-12-13 |
| WO2022169757A1 (en) | 2022-08-11 |
| MX2023009006A (es) | 2023-08-08 |
| CL2025003008A1 (es) | 2025-12-19 |
| US20240316154A1 (en) | 2024-09-26 |
| IL304219A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| MX2021000401A (es) | Nuevas proteinas de fusion especificas para cd137 y pd-l1. | |
| EA201300213A1 (ru) | Применение ингибиторов dpp iv | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| EA201800199A1 (ru) | Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| CO6390078A2 (es) | Inihibidores de syk de imidazopirazina | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| BR112014031788A2 (pt) | composições e métodos para o tratamento de diabetes | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| MX380480B (es) | Composiciones farmacéuticas que contienen insulina. | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
| Alcocer‐Gómez et al. | Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| JOP20240262A1 (ar) | المركبات المحتوية على البورون العطري ونظائر الأنسولين ذات الصلة | |
| CL2025003008A1 (es) | Fracciones que prolongan la semivida y métodos de uso de estas. | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| JOP20250174A1 (ar) | بروتينات اندماج il-12 fc |